Bellerophon Therapeutics is a clinical-stage biotherapeutics company founded in 2009, based in the United States. The company is dedicated to developing innovative products that combine novel drugs and devices for the treatment of cardiopulmonary and cardiac diseases. With a focus on addressing significant unmet clinical needs, Bellerophon Therapeutics' mission is to deploy well-studied molecules through innovative delivery systems. The company recently received a $5.00M Post-IPO Equity investment on 06 March 2023. This investment further underscores the potential and promise of Bellerophon Therapeutics as it continues to advance its groundbreaking approach to treating critical medical conditions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $5.00M | - | 06 Mar 2023 | |
| Post-IPO Equity | $43.70M | - | 18 May 2020 | |
| Post-IPO Equity | $15.30M | - | 30 Mar 2020 | |
| Post-IPO Equity | $7.00M | - | 22 Jan 2019 | |
| Post-IPO Equity | $3.00M | - | 11 May 2017 |
No recent news or press coverage available for Bellerophon Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
